2026-10-14T01:01:27Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33717766 2026-09-14T04:31:26Z category_388 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025.zip Junhua Li (125998) Chenhao Tang (24867688) Longfei Yang (435484) Chen Song (216175) Huixian Pan (24867691) Oncology and Carcinogenesis not elsewhere classified bibliometrics bladder cancer cfDNA ctDNA liquid biopsy molecular residual disease urothelial carcinoma Background<p>Circulating tumour DNA (ctDNA), cell-free DNA (cfDNA) and urinary tumour DNA are increasingly studied in bladder cancer and urothelial carcinoma. We mapped the development, knowledge structure and clinical emphasis of this ctDNA/cfDNA-centred literature and assessed its coverage across three bibliographic databases.</p>Methods<p>Web of Science Core Collection (WoSCC), Scopus and PubMed/MEDLINE were searched on July 31, 2026, for records published in 2008-2025. Reviewer-expanded strategies included liquid biopsy, ctDNA/cfDNA, molecular residual disease, molecular relapse, tumour-informed assays, urinary DNA, methylation, TERT and FGFR3. WoSCC was the primary mapping database; Scopus and PubMed/MEDLINE were coverage comparators. Python, VOSviewer and CiteSpace were used for descriptive and network analyses. Newly retrieved WoSCC records underwent duplicate independent screening and full third-reviewer quality control.</p>Results<p>The searches retrieved 1,903 WoSCC, 3,201 Scopus and 230 PubMed/MEDLINE records. After WoSCC deduplication and eligibility assessment, 494 records formed the main set and 698 formed a contextual set. The main set received 17,031 citations (median 19; interquartile range 7-42), and annual output reached 82 records in 2025. Scopus covered 456/494 main records and PubMed/MEDLINE covered 93/494. Among 557 newly assessed records, the reviewers initially agreed on 433 (77.7%; Cohen’s kappa, 0.620); all records then underwent third-reviewer full-text quality control.</p>Conclusions<p>The expanded search identifies a larger DNA-focused literature than the original strategy and confirms unequal database coverage. Thematic clusters and citation bursts trace a shift from early methylation-marker research towards ctDNA-based molecular residual disease assessment and perioperative treatment stratification. Bibliometric prominence describes research activity, not diagnostic accuracy, predictive validity or treatment benefit.</p> 2026-09-14T04:31:26Z Dataset Dataset 10.3389/fonc.2026.1906152.s001 https://figshare.com/articles/dataset/Data_Sheet_1_ctDNA-_and_cfDNA-based_liquid_biopsy_in_bladder_cancer_and_urothelial_carcinoma_bibliometric_mapping_and_cross-database_coverage_analysis_2008-2025_zip/33717766 CC BY 4.0